Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The REGENXBIO Inc. (RGNX) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer focused on AAV gene therapy, REGENXBIO uses current reports on Form 8-K and other filings to communicate material information about its operations, clinical programs, collaborations and financial condition.
Recent 8-K filings illustrate how the company reports key developments. One Form 8-K describes the issuance of a press release covering financial results and operational highlights for the quarter ended September 30, 2025, including updates on late-stage programs such as RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II and surabgene lomparvovec (ABBV-RGX-314, sura-vec) for retinal disease. Another 8-K details the FDA’s extension of the Prescription Drug User Fee Act (PDUFA) action date for the RGX-121 Biologics License Application for MPS II, moving the date to February 8, 2026 to allow review of additional data.
REGENXBIO also uses Form 8-K to disclose significant collaboration changes. An 8-K filed in August 2025 outlines a first amendment to the collaboration and license agreement with AbbVie, which modifies the development plan and milestone structure for the diabetic retinopathy program using suprachoroidal delivery and adds further AbbVie-led investment in the subretinal wet AMD program. The filing explains new milestone payment terms tied to first patient dosing in registration-enabling trials and references a joint press release attached as an exhibit.
On this page, investors can review such 8-Ks alongside other SEC documents to understand how REGENXBIO reports clinical milestones, regulatory interactions, collaboration amendments and financial results. Stock Titan’s tools can help surface the most recent filings, while AI-powered summaries can clarify the main points of lengthy documents, highlight items such as PDUFA date changes or collaboration amendments, and make it easier to follow how these disclosures relate to the company’s gene therapy pipeline and RGNX stock.
REGENXBIO has filed a prospectus for the potential resale of up to 268,096 shares of common stock by a selling stockholder. These shares are issuable through a warrant with an exercise price of $14.92 per share, connected to a May 2025 Loan Agreement with HealthCare Royalty Management.
Key financial points:
- Potential proceeds of $4.0 million if warrant is fully exercised
- Current stock price: $8.56 (as of June 24, 2025)
- Trading symbol: RGNX on Nasdaq Global Select Market
REGENXBIO is a clinical-stage biotechnology company focused on gene therapy using their proprietary NAV® Technology Platform. Their platform utilizes AAV vectors for gene delivery, including AAV8 and AAV9. The company has multiple ongoing clinical trials including AAVIATE®, AFFINITY BEYOND®, ALTITUDE®, and ATMOSPHERE®. Key partnerships include collaborations with AbbVie for ABBV-RGX-314 and Nippon Shinyaku for RGX-121 and RGX-111 development.